NASDAQ · GELS
Healthcare · Drug Manufacturers - Specialty & Generic
$0.58
Down-$0.01 (-1.97%)
Updated Sep 18, 2026, 7:28 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
GELS closed at $0.58 after 20 trading sessions, up 3.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $0.609 | $0.609 | $0.566 | $0.5797 | 63.42K |
| Sep 16, 2026 | $0.60 | $0.6324 | $0.5802 | $0.5802 | 85.34K |
| Sep 15, 2026 | $0.6675 | $0.6675 | $0.58 | $0.6156 | 103.75K |
| Sep 14, 2026 | $0.697 | $0.7099 | $0.65 | $0.6799 | 76.77K |
| Sep 11, 2026 | $0.7801 | $0.7801 | $0.70 | $0.7001 | 93.43K |
| Sep 10, 2026 | $0.784 | $0.87 | $0.64 | $0.7871 | 344.72K |
| Sep 9, 2026 | $0.66 | $0.85 | $0.6356 | $0.8497 | 700.23K |
| Sep 8, 2026 | $0.8338 | $0.8339 | $0.6322 | $0.6762 | 543.49K |
| Sep 4, 2026 | $0.805 | $0.90 | $0.7711 | $0.90 | 1.46M |
| Sep 3, 2026 | $0.9911 | $1.12 | $0.7493 | $0.8932 | 70.09M |
| Sep 2, 2026 | $0.5689 | $0.826 | $0.532 | $0.70 | 71.64M |
| Sep 1, 2026 | $0.5401 | $0.5512 | $0.5301 | $0.532 | 16.68K |
| Aug 31, 2026 | $0.5489 | $0.5489 | $0.5424 | $0.5458 | 4.26K |
| Aug 28, 2026 | $0.5701 | $0.575 | $0.5301 | $0.5555 | 11.76K |
| Aug 27, 2026 | $0.5654 | $0.5798 | $0.5512 | $0.5701 | 16.59K |
| Aug 26, 2026 | $0.587 | $0.587 | $0.56 | $0.5798 | 4.98K |
| Aug 25, 2026 | $0.526 | $0.589 | $0.526 | $0.5476 | 40.19K |
| Aug 24, 2026 | $0.539 | $0.5624 | $0.52 | $0.5317 | 17.85K |
| Aug 21, 2026 | $0.589 | $0.589 | $0.5366 | $0.5628 | 21.04K |
| Aug 20, 2026 | $0.5601 | $0.5797 | $0.53 | $0.5576 | 29.65K |
The latest Smart Investors Daily articles mentioning GELS.
GELS research
Company profile and research snapshot.
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Sep 10, 2026
Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 8.9% to $0.32 during Thursday's after-market session. The company's market cap stands at $11.5 million. Picard Medical (AMEX:PMI) stock moved upwards
ChartMill · Sep 9, 2026
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Benzinga · Sep 9, 2026
Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON) shares rose
Benzinga · Sep 8, 2026
Gainers InnovAge Holding (NASDAQ:INNV) shares increased by 10.8% to $11.65 during Tuesday's after-market session. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out today.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GELS.
No results
No recent SID articles mention GELS.
